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Abstract
Alexander disease is a fatal neurodegenerative disease caused by mutations in the astro-
cyte intermediate filament glial fibrillary acidic protein (GFAP). The disease is characterized
by elevated levels of GFAP and the formation of protein aggregates, known as Rosenthal
fibers, within astrocytes. Lithium has previously been shown to decrease protein aggre-
gates by increasing the autophagy pathway for protein degradation. In addition, lithium has
also been reported to decrease activation of the transcription factor STAT3, which is a regu-
lator of GFAP transcription and astrogliogenesis. Here we tested whether lithium treatment
would decrease levels of GFAP in a mouse model of Alexander disease. Mice with the
Gfap-R236H point mutation were fed lithium food pellets for 4 to 8 weeks. Four weeks of
treatment with LiCl at 0.5% in food pellets decreased GFAP protein and transcripts in sev-
eral brain regions, although with mild side effects and some mortality. Extending the dura-
tion of treatment to 8 weeks resulted in higher mortality, and again with a decrease in GFAP
in the surviving animals. Indicators of autophagy, such as LC3, were not increased, sug-
gesting that lithium may decrease levels of GFAP through other pathways. Lithium reduced
the levels of phosphorylated STAT3, suggesting this as one pathway mediating the effects
on GFAP. In conclusion, lithium has the potential to decrease GFAP levels in Alexander dis-
ease, but with a narrow therapeutic window separating efficacy and toxicity.
Introduction
Alexander disease is a rare and fatal neurodegenerative disease characterized by the formation
of protein inclusions, called Rosenthal fibers, in astrocyte cell bodies and processes. Nearly all
cases are associated with dominant mutations in the intermediate filament glial fibrillary acidic
protein (GFAP) [1], which appear to act in a gain-of-function fashion. Onset can occur
throughout the lifespan, with symptoms such as seizures and psychomotor developmental
delays common in the younger patients and difficulties with speech and swallowing, autonomic
dysfunction, and gait disturbances more common in the older patients [2]. Alexander disease
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is classified among the leukodystrophies because of the prominent defects in white matter that
are present, particularly in early-onset patients.
While the question of whether Rosenthal fibers themselves are toxic is unresolved, a leading
hypothesis to explain pathogenesis is that GFAP protein levels accumulate above a toxic thresh-
old (as yet undefined), leading to astrocyte dysfunction and the plethora of secondary effects on
the other cell types of the central nervous system [3]. Indeed, GFAP increases are consistently
found in Alexander disease, both when measured in brain parenchyma as well as in CSF [4, 5].
GFAP is a major component of the Rosenthal fibers, and in fact the formation of Rosenthal fibers
can be initiated simply by over-expressing even wild-type GFAP to high enough levels [6]. The
accumulation of GFAP that is found in Alexander disease results in part from increased synthe-
sis, as mRNA levels are increased [7] and there is a spontaneous increase in the activity of the
GFAP promoter [8]. In addition, complex changes occur in the degradation pathways. For
instance, Alexander disease mutant GFAP activates a c-Jun N-terminal kinase (JNK) stress
response that blocks proteasome activity [9, 10]. Together, the alterations in synthesis and degra-
dation could lead to positive feedback loops that exacerbate GFAP accumulation.
Reducing the GFAP accumulation below toxic levels has been proposed as one potential
strategy for treatment [11]. Considering degradation pathways as a therapeutic target, one pos-
sibility to reduce protein aggregation is the induction of autophagy. Autophagy (macro-autop-
hagy) is a non-specific degradative pathway for long-lived cytoplasmic proteins, protein
complexes, and organelles [12]. Autophagy-inducing drugs have proved useful for decreasing
protein aggregates in models of other neurodegenerative disorders, such as Huntington’s dis-
ease, Parkinson’s disease, spinocerebellar ataxia, and tauopathy [13–17]. Indeed, based largely
on cell culture models, autophagy appears to be naturally increased in Alexander disease
patients, and autophagy contributes to the degradation of GFAP [4]. We hypothesized that
increasing autophagy further in Alexander disease might lower levels of the protein.
Lithium is an autophagy-inducing drug that is commonly used as a mood stabilizer for the
treatment of bipolar disorder and major depression. In cell culture models of Huntington’s dis-
ease and Parkinson’s disease, lithium increases autophagy through the inhibition of inositol
monophosphatase 1 (IMPase) [15], though it has also been reported to decrease autophagy
through inhibition of GSK-3β and activation of mTOR [18] (Fig 1). Lithium also affects a vari-
ety of other pathways and is neuroprotective in several models of neurodegenerative diseases
including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral
sclerosis (ALS), and tauopathy (reviewed in [19]). Some protective effects associated with lithium
include increased anti-apoptotic proteins, increased hippocampal neurogenesis, increased mito-
chondrial energetic function, reduced oxidative stress, stimulation of neurotrophic factors, and a
decreased inflammatory response (reviewed in [19]). Lithium also decreases the activity of
STAT3 (signal transducer and activator of transcription 3) [20–22], a transcription factor that
regulates astrogliosis and promotes GFAP transcription [23] (Fig 1). Previous studies have shown
that lithium can reduce activated STAT3 and decrease GFAP in rodent models of ALS, taxol-
induced neuropathic pain, and lipopolysaccharide (LPS)-induced inflammation [21, 24, 25].
Due to its reported effects on autophagy, STAT3, and GFAP, we sought to test whether lithium
could decrease GFAP levels in a mouse model of Alexander disease. Gfap-R236H knock-in mice
have a mutation homologous to the common R239Hmutation in humans and replicate several
features of the disease, including elevated GFAP, Rosenthal fibers, an increased stress response,
and an increased susceptibility to seizures [26]. We found that lithium treatment decreased GFAP
protein and transcripts in several brain regions and spinal cord of Gfapmutant mice, though with
side effects and fatalities that were dose-dependent. Markers for autophagy were unchanged,
although there was diminished activation of STAT3, indicating that lithiummay decrease GFAP
levels through transcriptional regulation rather than protein degradation pathways.
Lithium Treatment of Alexander Disease Mice
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Materials and Methods
Ethics Statement
All studies were carried out in accordance with the recommendations of the National Institutes
of Health Guide for the Care and Use of Lab Animals and were approved by the Graduate
School Animal Care and Use Committee at the University of Wisconsin-Madison (protocols
G00199, G00321, and G00549).
Mice
Knock-in mice with the Gfap-R236H point mutation were generated as previously described [26]
and maintained as heterozygotes in the FVB/N background as previously described [27]. Gfap-luc
transgenic mice express firefly luciferase under the control of 12 kb of the mouse Gfap promoter
[28] and were also maintained in the FVB/N background. Mice were housed on a 10 h / 14 h
dark / light cycle with 2–5 mice per cage. Male and female R236H/+ mice and +/+ littermates were
used for experiments and data from each sex were analyzed separately unless otherwise indicated.
Attempts were made to blind researchers to drug treatment, but due to increased urination and
other mild side effects caused by LiCl, it became obvious which mice were receiving the LiCl and
further efforts were not made to continue “blinding” the studies. Mice were treated in ascending
order of identification number, with younger mice having higher identification numbers (newest
litters were treated last). All sample processing and initial data analysis were done without knowl-
edge of genotype or drug treatment. During all studies, mice were monitored at least once daily.
Mice that were found to be inactive and unable to easily access food or water were euthanized.
Lithium treatment via intraperitoneal injection
After genotyping, male and female mice were randomly assigned to the lithium or vehicle treat-
ment groups. A single cage could contain mice from any or all of the 4 experimental groups
Fig 1. Potential pathways of lithium action on autophagy and GFAP expression. Lithium can inhibit
GSK3β directly, via competition with Mg++, and indirectly through Akt/PKB. Inhibition of GSK3β occurs
through phosphorylation (P) at Serine 9 (S9). Disinhibition of mTOR can then lead to a decrease in
autophagy. Lithium can also increase autophagy through the IMPase pathway. Alternatively, lithium can
inhibit STAT3 directly, or indirectly through GSK3β, by decreasing its phosphorylation at tyrosine 705 (Y705).
STAT3 is then prevented from translocating to the nucleus where it would normally bind to the GFAP
promoter and activate transcription. Red text indicates inhibition and blue text indicates activation of
pathways by lithium.
doi:10.1371/journal.pone.0138132.g001
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(+/+ vehicle, +/+ LiCl, R236H/+ vehicle, and R236H/+ LiCl). Beginning at 6 wks of age, mice
were injected intraperitoneally (i.p.) at approximately the same time each day for 30 d with a
0.6 M LiCl solution (Sigma, St. Louis, MO, USA) diluted in phosphate buffered saline (PBS) at
a dose of 6 mmol/kg (10 μL per 10 g mouse) based on a protocol from Noble et al. [16]. Vehicle
control mice received injections of PBS. Mice were weighed daily at the time of injection. In
addition to the normal water bottle, cages contained an extra bottle of 450 mMNaCl to help
prevent electrolyte imbalances that might occur with lithium treatment.
Lithium treatment via 0.3% LiCl food pellets
Female mice were randomly assigned to the lithium or control diet treatment groups and
housed in 4 large cages (2 for lithium, 2 for control diet) with up to 10 mice of both genotypes
in each cage. Beginning at 6 wks of age, mice were fed rodent pellets (LabDiet 5015) containing
0.3% LiCl, based on a protocol from Tajes et al. [29]. LiCl was added to pellets by Teklad Diets,
Harlan Laboratories, Inc. Control diet mice received LabDiet 5015 pellets without LiCl. Control
diet and lithium mice were provided with an extra bottle of 450 mMNaCl during the
treatment.
Lithium treatment via 0.5% or 0.7% LiCl food pellets
Whole cages of 2–5 mice were randomly assigned to the lithium or control diet treatment
groups [30, 31]. A single cage could contain mice of one or both genotypes (+/+ and R236H/
+). Beginning at 6 wks of age, mice were fed pellets (LabDiet 5015) containing 0.2% LiCl for 1
wk, followed by 0.5% LiCl for 3 wks (4 wks total LiCl treatment) or 7 wks (8 wks total LiCl
treatment) based on a protocol from Bersudsky et al. [32]. For 0.7% LiCl treatment, 6 wk old
mice were fed pellets containing 0.2% LiCl for 1 wk followed by 0.7% LiCl for 3 wks (4 wks
total LiCl treatment). Control diet mice received LabDiet 5015 pellets without LiCl for the
whole treatment period. Control diet and lithium mice were provided with an extra bottle of
450 mMNaCl during the treatments. Mice were weighed weekly.
Blood collection and lithium measurement
Mice were anesthetized with isoflurane and blood collected from axillary vessels. Mice were
decapitated and brain collected as described below. Blood was allowed to clot for 2 h at room
temperature, centrifuged at 2,000 x g for 10 min, and serum (supernatant) was stored at -80°C.
After blood was collected from all mice in an experiment, 3–4 cages were randomly chosen per
experimental group, and at least one mouse serum sample from each of those cages was ran-
domly selected for analysis. If more than one mouse sample was used per cage, those values
were averaged first before averaging with other samples. Li concentration was measured using
flame atomic absorption spectrometry at the Wisconsin State Laboratory of Hygiene.
Tissue collection
Mice were anesthetized and decapitated (as described above) or sacrificed by CO2. Brains were
removed and dissected in ice-cold PBS into hemispheres and then regions, so that regional
samples are from one half of each brain. The specific regions collected included olfactory bulb,
corpus callosum, hippocampus, cerebral cortex overlying the hippocampus and underlying
white matter (abbreviated as ‘cortex’), cerebellum, brain stem, and cervical spinal cord (includ-
ing segments 1–3). These regions were selected based on previous studies in mouse showing
locations of prominent pathology (olfactory bulb, hippocampus, and corpus callosum) [26]
and based on areas of common involvement in human Alexander disease cases (white matter,
Lithium Treatment of Alexander Disease Mice
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brain stem, and cervical spinal cord) [3]. Tissues were immediately frozen in liquid nitrogen
and stored at -80˚C until further analysis.
Quantitative PCR
Quantitative PCR (qPCR) was performed using tissues from male mice treated with 0.5% LiCl
in food for 4 wks. For each experimental group, 4–5 cages were randomly selected, then tissues
from one randomly chosen mouse from each of those cages were used for qPCR. Brain regions
were homogenized in 500 μL Trizol (Invitrogen/Life Technologies) using a Geno/Grinder
(OPS Diagnostics LLC) at 1750 rpm for 3 min. Total RNA was isolated and purified using Tri-
zol according to the manufacturer’s instructions. RNA concentration was quantified on a
NanoDrop spectrophotometer (Thermo Fisher Scientific, Inc.) and converted to cDNA using
Superscript III reverse transcriptase as in the manufacturer’s instructions (Invitrogen/Life
Technologies). Primers were designed and standards generated as previously described [7] and
as follows: Gfap (Accession # NM_010277)–forward (F)—GAC TGT GGA GAT GCG GGA
TGG TGA, reverse (R)—GTG CTG GTG TGG GTG GGA ACT GAG; Nqo1 (Accession #
NM_008706)–F—CGG TAT TAC GAT CCT CCC TCA ACA, R—AGC CTC TAC AGC
AGC CTC CTT CAT; 18S ribosomal RNA (Accession # NR_003278)–F—CGC CGC TAG
AGG TGA AAT TCT, R—CGA ACC TCC GAC TTT CGT TCT; TATA box binding protein
(Tbp, Accession # NM_013684)–F—GCA CAG GAG CCA AGA GTG A, R—CCC ACC ATG
TTC TGG ATC TT; β-actin (Actb, Accession # NM_007393.3)–F—GCT GGT CGT CGA
CAA CGG CTC, R—CAA ACA TGA TCT GGG TCA TCT TTT C. Reactions were performed
in triplicate for standards and duplicate for samples with Power SYBR Green PCRMaster Mix
(Applied Biosystems/Life Technologies) on an Applied Biosystems 7500 Real-Time PCR Sys-
tem. Relative concentrations were calculated based on standard curves and normalized to at
least two of the following: 18S ribosomal RNA, Tbp, or β-actin. Similar results were obtained
with normalization to 18S, Tbp, and β-actin, therefore one set of representative data is pre-
sented in the Results and the reference gene used is indicated in the Figure legends.
GFAP ELISA
ELISAs were performed to quantify GFAP in tissues as previously described [27]. Briefly, tis-
sues were homogenized in 3.5 mL (brain hemisphere), 0.4 mL (olfactory bulb, corpus callosum,
hippocampus, cortex, cervical spinal cord), or 0.8 mL (brain stem, cerebellum) 2% sodium
dodecyl sulfate (SDS), 50 mM Tris (pH 7.4), 5 mM EDTA (pH 7.4), 1X cOmplete Protease
Inhibitor Cocktail (Roche Diagnostics Corp.) and 1 mM Pefabloc (Sigma) using a Geno/
Grinder, then boiled for 15 min. Total protein concentration was measured using the Pierce
BCA Protein Assay kit (Thermo Fisher Scientific). For tissues, samples and GFAP standards
were diluted in PBS with 0.5% Triton-X and 1% BSA. For sandwich ELISA, plates were coated
with SMI-26 (1:1000, anti-GFAP monoclonal cocktail, Covance), blocked with 5% non-fat dry
milk, incubated with samples and standards, then incubated with polyclonal rabbit anti-cow
GFAP (1:5000; Z0334, Dako), followed by goat anti-rabbit-HRP (1:10,000), then SuperSignal
ELISA Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). Chemiluminescence
was measured on a GloRunner microplate luminometer (Turner Biosystems).
Luciferase assay forGfap promoter activity
Luciferase assays were performed using tissues from Gfap-luc-positive R236H/+ and +/+ mice
using the ONE-Glo Luciferase Assay System (Promega Corporation) according to the manu-
facturer’s instructions. Briefly, tissues were homogenized in 300 μL (olfactory bulb, corpus cal-
losum, hippocampus, cortex, cervical spinal cord) or 500 μL (brain stem, cerebellum) of Glo-
Lithium Treatment of Alexander Disease Mice
PLOS ONE | DOI:10.1371/journal.pone.0138132 September 17, 2015 5 / 19
Lysis buffer for 4 min at 1750 rpm using a Geno/Grinder and centrifuged at 1,370 x g for 20 min
at 4°C. 40 μL of supernatant was mixed with 40 μL of luciferase substrate, incubated for 3 min,
and luminescence was measured on a GloRunner microplate luminometer. Luminescence was
normalized to total protein concentration measured using the Pierce BCA Protein Assay kit.
Immunoblots
Total protein lysates used for ELISAs (in 2% SDS lysis buffer) were also used for immunoblotting.
Samples were diluted in Laemmli buffer, boiled for 15 min, equal amounts of protein loaded
onto 10% or 4–20% Criterion TGX precast gels (Bio-Rad), and transferred onto Immobilon-FL
membranes (EMDMillipore Corporation). Membranes were blocked in SEA BLOCK (Thermo
Scientific) and incubated with the following primary antibodies: rabbit anti-LC3 (1:1000 with
4–20% gel; NB100-2331, Novus Biologicals LLC), mouse anti-P62 (1:2000; 2C11, Abnova),
mouse anti-GAPDH (1:10,000; 10R-G109A, Fitzgerald Industries International), rabbit anti-
GAPDH (1:2500; ab9485, Abcam), rabbit anti-phospho-GSK-3α/β (Ser21/9) (1:1000; 9331, Cell
Signaling Technology), and rabbit anti-STAT3-pY705 (1:2000; 9145, Cell Signaling Technology).
Membranes were incubated with goat anti-rabbit Dialyte 800 (1:10,000; 35571, Thermo Scien-
tific) and goat anti-mouse Alexa 680 (1:10,000; A21057, Invitrogen) and scanned on the Odyssey
(LI-COR Biosciences). Analysis of blots was performed using Image Studio (LI-COR). LC3, p62,
p70S6K, phospho-p70S6K, and phospho-GSK-3α/β were also detected with the following proto-
col. Membranes were blocked in 10% non-fat milk in PBS-Triton X-100, then incubated with
one of the following antibodies: mouse anti-LC3 (1:400; 5H3, Nanotools), p62 (1:1000; P0067,
Sigma), p70S6K (1:1000; 9202, Cell Signaling), phospho-p70S6K (1:1000; 9205, Cell Signaling),
and rabbit anti-phospho-GSK-3α/β (Ser21/9) (1:1000, 9331, Cell Signaling). Membranes were
incubated with anti-mouse or anti-rabbit secondary antibodies conjugated with horseradish per-
oxidase (1:20,000; Sigma) and developed using ECL solution (GE Healthcare).
Statistical analysis
For body weight, ELISA, and Gfap promoter activity in the 0.5% and 0.7% LiCl experiments,
cages were considered the unit of analysis, so that mice of the same genotype within a cage
were averaged to yield a single data point [30, 31]. Results from several cages were then aver-
aged to yield means and standard errors (SEM). Numbers of mice and cages are specified in
the Results section. Comparisons among the four experimental groups were done using one-
way ANOVA with post Bonferroni t-tests for 4 selected comparisons (+/+ control diet vs.
+/+ LiCl, R236H/+ control diet vs. R236H/+ LiCl, +/+ control diet vs. R236H/+ control diet,
and +/+ control diet vs. R236H/+ LiCl). Due to space limitations, only samples from a single
brain region could be run on each ELISA, luciferase assay, or qPCR 96-well plate. Since some
variability occurs between plates, statistical comparisons were not made between brain regions.
For body weight analysis, statistical comparisons were made only at the final time point in each
experiment. The significance level was defined as 0.05 and P< 0.05, P< 0.01, P< 0.001,
P< 0.0001 in all figures. Statistical analyses were performed using GraphPad Prism 5.01
(GraphPad Software).
Results
0.5% LiCl in food pellets for 4 wks decreases GFAP in surviving R236H/
+ mice
To test whether lithium can improve the phenotype of a mouse model of Alexander disease, we
treated mice with lithium using several different methods. In preliminary experiments, we
Lithium Treatment of Alexander Disease Mice
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employed daily i.p. injections for 30 d (S1 Fig) or 0.3% LiCl in food pellets for 30 d (S2 Fig), but
neither decreased GFAP protein in more than one of the six brain regions tested. We then
increased the dose and fed mice food pellets containing 0.5% LiCl. Beginning at 6 wks of age,
male and female mice were fed 0.2% LiCl food for 1 wk, followed by 0.5% LiCl food for 3 wks.
94.7% (36/38) of the R236H/+ mice fed LiCl survived the 4 wks of treatment, while all of the
+/+ control diet (22/22), +/+ LiCl (22/22), and R236H/+ control diet (37/37) mice survived
(Fig 2A). Mice treated with this dose of LiCl showed mild side effects, including polyuria and
Fig 2. LiCl administered via 0.5% LiCl food pellets for 4 wks decreases GFAP levels inGfap-R236H/+ mice. (A) Survival analysis for mice treated with
0.5% LiCl in food pellets for 4 wks. 94.7% (36/38) R236H/+ mice survived LiCl treatment while 100% of mice in other groups survived. (B) Concentrations of
lithium in serum at the end of 4 or 8 wk treatments (N = 3 cages, 4 mice per genotype for 4 wks and N = 3 cages, 3–4 mice per genotype for 8 wks). (C) LiCl-
treated +/+ and R236H/+ male mice had lower body weights compared with control-treated mice (N = 3–5 cages, 5–9 mice per group). (D) 0.5% LiCl
treatment decreased GFAP in olfactory bulb, hippocampus, parietal cortex including underlying white matter (cortex) and cervical spinal cord of R236H/
+ male mice as measured by ELISA (N = 3–5 cages, 5–9 mice per group). (E) 0.5% LiCl treatment decreasedGfap transcript levels relative to Tbp in all
regions except cerebellum of R236H/+ male mice (N = 4–5 mice per group). Error bars are SEM in B-D and SD in E. ****P < 0.0001, ***P < 0.001,
**P < 0.01, *P < 0.05. * is versus +/+ control in C.
doi:10.1371/journal.pone.0138132.g002
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occasional jitteriness. The two mice that died during treatment (1 male, 1 female) had no addi-
tional signs of illness before being found dead. Lithium concentrations in the serum were mea-
sured in a subset of surviving mice on the last day of treatment and found to be 1.6 ± 0.3 mM
in +/+ mice, and 2.1 ± 0.3 mM in R236H/+ mice (Fig 2B). Mice fed the control diet had unde-
tectable levels of lithium (N = 3 cages, 3 mice;< 0.1 mM).
R236H/+ mice typically weigh less than +/+ littermates, and we next tested whether LiCl
treatment improved the body weight phenotype. However, R236H/+ LiCl mice maintained a
steady weight during the course of treatment and did not gain weight like control-fed litter-
mates (Fig 2C). Wild type mice fed the LiCl diet experienced mild weight loss during the 4 wks
of treatment (Fig 2C).
We next tested the effect of 0.5% LiCl treatment on GFAP levels in the mice. Using a GFAP
ELISA, we found that the 0.5% LiCl food treatment for 4 wks decreased GFAP protein levels in
several brain regions of male and female R236H/+ mice, with minor variations between the
sexes. In male R236H/+ mice, LiCl decreased GFAP protein in olfactory bulb, hippocampus,
cortex, and cervical spinal cord (Fig 2D), while in female R236H/+ mice, LiCl decreased GFAP
in hippocampus, cortex, brain stem, cerebellum, and cervical spinal cord (S3 Fig). GFAP pro-
tein did not change in any regions of +/+ mice treated with 0.5% LiCl.
We next analyzed GFAP expression at the level of mRNA. Gfap transcript levels changed in
a pattern similar to protein levels. In male R236H/+ mice, LiCl decreased Gfap transcripts in
olfactory bulb, hippocampus, cortex, brain stem, and cervical spinal cord, while LiCl did not
change Gfap transcript levels in +/+ mice (Fig 2E).
0.7% LiCl in food pellets for 4 wks does not further decrease GFAP
We next tested whether a higher dose of 0.7% LiCl would have a greater effect, but this dose in
food pellets for 4 wks did not further decrease GFAP compared with the 0.5% LiCl treatment.
LiCl at 0.7% decreased GFAP only in cerebellum and cervical spinal cord of male R236H/+ mice,
and in olfactory bulb and cerebellum of female R236H/+ mice (S4 Fig). 93.8% (15/16) of the
R236H/+ mice fed LiCl survived the 4 wks of treatment, while all of the +/+ control diet (13/13),
+/+ LiCl (14/14), and R236H/+ control diet (18/18) mice survived. Lithium-treated mice showed
mild side effects, including polyuria and occasional jitteriness. Serum lithium levels in a subset of
surviving mice were 1.3 ± 1.0 mM in +/+ mice and 3.0 ± 0.7 mM in R236H/+ mice.
0.5% LiCl in food pellets for 8 wks decreases GFAP in surviving R236H/
+ mice
We next tested whether lengthening the duration of 0.5% LiCl treatment would further
decrease GFAP levels in R236H/+ mice. Beginning at 6 wks of age, male mice were fed 0.2%
LiCl for 1 wk, followed by 0.5% LiCl for 7 wks. For the 8 wk treatment, R236H/+ mice were
crossed with Gfap-luc transgenic mice that express luciferase under control of the mouse Gfap
promoter, in order to test the effects of lithium on Gfap promoter activity. Since mRNA levels
can also be regulated by degradation mechanisms, GFAP promoter activity can provide an
additional, more direct measure of GFAP transcriptional activity. The 8 wk treatment resulted
in a higher mortality rate among +/+ and R236H/+ mice receiving the 0.5% LiCl food, com-
pared with the 4 wk treatment. All of the +/+ control diet (10/10) and R236H/+ control diet (6/
6) mice survived until the end of the treatment, but only 81.8% (9/11) of +/+ LiCl and 54.5%
(6/11) of R236H/+ LiCl mice survived 8 wks of treatment (Fig 3A). The seven mice that did not
survive died at or after 4 wks of treatment. Two of the mice (one +/+, one R236H/+) were
lethargic with some possible tremors and after 1–2 h of observation and unsuccessful attempts
to help them eat and drink, the mice were euthanized. The remaining five mice (one +/+, four
Lithium Treatment of Alexander Disease Mice
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R236H/+) were jittery on occasion, but displayed no other signs of illness before being found
dead. Serum lithium levels were higher in R236H/+ mice (2.4 ± 0.2 mM) compared with
+/+ mice (1.2 ± 0.1 mM; Fig 2B). Mice fed the control diet had undetectable levels of lithium
(N = 3 cages, 3 mice;< 0.1 mM). Similar to the 4 wk treatment, R236H/+ mice maintained a
steady weight throughout the treatment, neither gaining nor losing significant body weight
Fig 3. LiCl administered via 0.5% LiCl food pellets for 8 wks decreases GFAP levels in survivingGfap-
R236H/+mice. (A) 81.8% (9/11) +/+ mice and 54.5% (6/11) R236H/+ mice survived 8 wks of LiCl treatment.
All mice survived control diet treatment. (B) LiCl-treated +/+ and R236H/+ male mice had lower body weights
compared with control-treated mice (N = 4–6 cages, 6–11 mice per group). (C) 0.5% LiCl treatment
decreased GFAP in corpus callosum, parietal cortex including underlying white matter (cortex), brain stem,
cerebellum, and cervical spinal cord of R236H/+ male mice as measured by ELISA (N = 3–4 cages, 4–6 mice
per group). (D) 0.5% LiCl decreasedGfap promoter activity in hippocampus, cortex, brain stem, cerebellum,
and cervical spinal cord of R236H/+;Gfap-lucmice (N = 3–5 cages, 4–5 mice per group). Error bars are SEM.
****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. * is versus +/+ control in B.
doi:10.1371/journal.pone.0138132.g003
Lithium Treatment of Alexander Disease Mice
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(body weight analysis includes all available data from mice euthanized or found dead; Fig 3B).
+/+ mice had mild weight loss through the 4 wk time point, then maintained a steady weight
until 8 wks (Fig 3B).
We next quantified GFAP protein levels and found that 0.5% LiCl treatment for 8 wks
decreased GFAP in corpus callosum, cortex, brain stem, cerebellum, and cervical spinal cord of
surviving R236H/+ mice (Fig 3C). Using a cross to a Gfap-luciferase reporter mouse to provide
an indirect measure of promoter activity (previously shown to be increased in the R236H/
+ mice [8]), we found that Gfap promoter activity was also decreased in hippocampus, cortex,
brain stem, cerebellum, and cervical spinal cord of the GFAP mutants that survived lithium
treatment (Fig 3D).
0.5% LiCl in food pellets for 4 wks decreases the antioxidant stress
response
R236H/+ mice have an elevated antioxidant stress response, implying oxidative stress, that
increases with age [26], and we next wanted to test whether LiCl treatment would decrease this
stress response. Nrf2 (Nfe2l2, nuclear factor, erythroid derived 2, like 2) is a transcription factor
that regulates many genes involved in the protective antioxidant stress response and is elevated
in R236H/+ mice [26]. We examined cortex and hippocampus of male mice and found that
0.5% LiCl food decreased Nrf2 transcripts in the R236H/+ mice (Fig 4A). NAD(P)H dehydro-
genase, quinone 1 (Nqo1) is an antioxidant enzyme that is regulated by Nrf2 and transcripts of
Nqo1 are elevated in R236H/+ mice [27]. 0.5% LiCl decreased Nqo1 transcript levels in cortex
and hippocampus of R236H/+ mice (Fig 4B). These results indicate that the antioxidant stress
response is decreasing in regions where lithium decreases GFAP.
0.5% LiCl in food pellets for 4 wks does not increase autophagy in
R236H/+ mice
Previous studies have shown that lithium can increase autophagy through the IMPase pathway
[15], and increasing autophagy with rapamycin decreases GFAP levels in astrocytoma cells
expressing Alexander disease mutant GFAP [4]. Although there is some evidence that autop-
hagy is spontaneously elevated in Alexander disease [4], we considered whether the lithium-
induced decrease in GFAP might be associated with a further increase in this degradation path-
way. LC3-II is found in phagophore and autophagosome membranes and is commonly used as
an indicator of autophagosome number [33] (reviewed in [34]). Immunoblotting showed
LC3-II and the LC3-II / LC3-I ratio were not different between control diet +/+ and control
diet R236H/+ mice. In addition, 0.5% LiCl for 4 wks did not change LC3-II levels or LC3-II /
LC3-I ratios in female R236H/+ cortex, a region where LiCl decreased GFAP levels (Fig 5A and
5B). To confirm that LiCl was decreasing GFAP in the absence of an increase in autophagy, we
also examined p70S6K, a substrate of mTOR involved in autophagy (reviewed in [35]). Consid-
erable variability in phosphorylated p70S6K (phospho-p70S6K) and total p70S6K between
mice resulted in no overt changes with lithium treatment (S5A and S5B Fig). P62 is a substrate
of autophagy that also accumulates in Rosenthal fibers [36]. We found that P62 was increased
in control diet R236H/+ mouse olfactory bulb compared with control diet +/+, but lithium
treatment did not change P62 levels (Fig 5C and 5D). Lithium treatment also did not change
P62 levels in cortex (S5E and S5F Fig). Together, these results suggest that 0.5% LiCl for 4 wks
does not increase autophagy.
Lithium is thought to exert some of its effects on brain through the GSK3β pathway. Lith-
ium both directly inhibits GSK3β and also indirectly inhibits GSK3β through phosphorylation
at serine 9 (pS9-GSK3β), a pathway through which it may inhibit autophagy and promote
Lithium Treatment of Alexander Disease Mice
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STAT3 activity [20]. We found that 0.5% LiCl for 4 wks did not consistently increase
pS9-GSK3β in cortex (data not shown) or hippocampus (S5C and S5D Fig). This indicates that
the effects of lithium on GFAP levels may not involve GSK3β.
0.5% LiCl in food pellets for 4 wks inhibits STAT3
Another pathway through which lithium may be decreasing GFAP is the Janus kinase (JAK)-
signal transducer and activator of transcription (STAT) pathway. STAT3 is a transcription
Fig 4. LiCl administered via 0.5% LiCl food pellets for 4 wks decreases the antioxidant stress
response. (A) LiCl decreases Nrf2 transcripts in hippocampus and cortex of R236H/+ mice (N = 5 male mice
per group). (B) LiCl decreasesNqo1 transcript levels in hippocampus and cortex of R236H/+ mice (N = 4–5
male mice per group). Error bars are SD. Data are normalized to 18S. ****P < 0.0001, ***P < 0.001,
**P < 0.01, *P < 0.05.
doi:10.1371/journal.pone.0138132.g004
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factor involved in astrogliogenesis and regulation of GFAP [23] and reactive astrogliosis [37].
Phosphorylation of STAT3 at Tyr-705 (pY705-STAT3) by the JAK family of kinases is required
for its activation and translocation to the nucleus (reviewed in [38]). Lithium has been shown
to inhibit STAT3 and suppress astrogliogenesis in culture by decreasing pY705-STAT3 [22].
Using immunoblotting, we found that pY705-STAT3 was undetectable in +/+ control diet
mice and increased in R236H/+ control diet mice (Fig 6), indicating that the R236H mutation
increases activation of STAT3. In R236H/+ mice, 0.5% LiCl treatment for 4 wks caused a small
but consistent decrease in pY705-STAT3 in all 3 brain regions examined: olfactory bulb, hippo-
campus, and cortex (Fig 6). These results suggest that lithium may be decreasing GFAP in
R236H/+ mice through effects on STAT3 phosphorylation.
Discussion
Alexander disease is a fatal neurodegenerative disorder for which only supportive treatments exist.
For such a rare disorder (incidence less than 1 in a million based on one study [39]), identifying
potential therapeutics from drugs that are already approved by the FDA is a promising approach.
Lithium has a long history of application in the treatment of bipolar disorder, and in experimental
studies is protective in several models of neurodegenerative diseases. Based on previous reports
that lithium increases the autophagy pathway for protein degradation [15, 18], and other studies
where lithium treatment was associated with a decrease in GFAP itself [21, 24, 25], we tested
whether lithium would decrease GFAP accumulation in a mouse model of Alexander disease. We
show here that lithium treatment decreases GFAP levels in several brain regions of R236H/+ mice,
but likely through transcriptional mechanisms, and with a narrow therapeutic range.
Molecular mechanisms of lithium action
Previous studies have indicated that mutant GFAP can be degraded through autophagic mech-
anisms, possibly involving reduction in mTOR activity [4]. In a previous study, LC3-II,
Fig 5. LiCl administered via 0.5% LiCl food pellets for 4 wks does not increasemarkers for autophagy inGfap-R236H/+mice. Each lane of the
immunoblots is tissue from one mouse. Immunoblots for LC3-I and LC3-II in (A) did not detect a change in parietal cortex (and underlying white matter) with
LiCl treatment. LC3-II bands normalized to LC3-I are quantified in B (N = 3–4 mice from 3–4 cages per genotype, and is representative of 3 blots). LC3-II
normalized to GAPDH gave similar results and is not shown. P62 was increased in control diet R236H/+ mouse olfactory bulb compared with control diet +/+,
but LiCl did not change P62 levels in GFAP+/+ or R236H/+ mice (C-D). P62 was normalized to total protein loaded. Error bars are SEM. ****P < 0.0001.
doi:10.1371/journal.pone.0138132.g005
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commonly used as an indicator of autophagosome number, was increased in astrocytes cul-
tured from GFAP-R236H/+ mice, autophagic vacuoles were detected near Rosenthal fibers in
R236H/+ mouse brain, and LC3-II was increased and phospho-mTOR and phospho-p70S6K
were both decreased in human astrocytoma cell lines expressing mutant GFAP [4]. In contrast,
we did not detect changes in LC3-II, the LC3-II / LC3-I ratio, phospho-p70S6K, or total
p70S6K in R236H/+ mice compared with wild-type mice. Tang et al. [4] also did not detect a
change in total p70S6K levels in mutant GFAP expressing cells, though they did detect a
decrease in phospho-p70S6K. Studies in mouse brain could be complicated by the contribu-
tions of other cell types that mask specific effects in astrocytes.
Fig 6. LiCl administered via 0.5% LiCl food pellets for 4 wks decreases pY705-STAT3 (pSTAT3) levels
in GFAP-R236H/+ mice.Representative immunoblots for pSTAT3 in olfactory bulb (A), hippocampus (C),
and parietal cortex including underlying white matter (E). pSTAT3 bands normalized to GAPDH are quantified
in B, D, and E (N = 3–4 mice from 3–4 cages per group; quantification is of main dark band; uncropped blots
are in S6 Fig). Error bars are SD. **P < 0.01, *P < 0.05.
doi:10.1371/journal.pone.0138132.g006
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Previous studies suggest that lithium can increase autophagy through the IMPase pathway
[15], but we did not detect changes either in autophagosome markers (such as LC3-II) or
mTOR pathway proteins (such as p70S6K) in lithium-treated mice. It remains possible that
lithium increased autophagic flux while autophagosome number (and LC3-II) remained stable.
Autophagy is also known to be induced via the mTOR pathway, previously shown to be acti-
vated in cell lines expressing mutant GFAP [4]. However we observed a high degree of variabil-
ity, and consequently no significant change, in the levels of phospho-p70S6K and p70S6K with
lithium treatment, indicating autophagy was not affected via the mTOR pathway. However,
p70S6K activity would not be expected to change if lithium acts through an mTOR-indepen-
dent pathway, a possibility suggested by previous studies [15].
GFAP is also regulated by the proteasome system [9, 10] and it is possible lithium could
decrease GFAP levels by increasing proteasome activity or by increasing the efficiency of
GFAP degradation by the proteasome. To our knowledge, there is no evidence for a direct
effect of lithium on the proteasome, but increased proteasomal degradation of GFAP could be
a secondary effect of a decreased stress response and mutant GFAP [9, 10].
In addition to its potential effects on degradation of GFAP, lithium could also influence
GFAP levels through transcriptional control. The transcription factor STAT3 is involved in
astrocyte differentiation [23, 40] and reactive gliosis [37], and it has a known binding site in
the GFAP promoter [23]. Previous studies indicate lithium may inhibit STAT3 through the
serine/threonine kinase GSK3 [20, 21] (Fig 1). GSK3 is normally active and becomes inacti-
vated when phosphorylated, for example, upon lithium treatment [41, 42]. Previous studies
showed increased autophagy and inhibition of GSK3β in lithium treated mice [16, 24], but in
our experiments, lithium did not consistently increase phosphorylated GSK3β. Our inability to
replicate the effect of lithium on GSK3βmay be related to mouse strain-dependent effects of
lithium [43]. Nevertheless, our results suggest that decreases in pSTAT3 and GFAP occur inde-
pendently of GSK3β. Zhu et al. also found that lithium may inhibit STAT3 independently of
GSK3 [22]. Lithium has many effects in the brain [44], and it remains possible that its effects
on STAT3 activation are indirect, due to suppression of gliosis through other pathways.
Interestingly, lithium treatment did not decrease GFAP in +/+ mice, in whom pSTAT3 was
undetectable. This suggests the effects of lithium were specific to R236H/+ mice who had ele-
vated pSTAT3 and supports the possibility that lithium decreases GFAP through STAT3
inhibition.
As indicators of the antioxidant stress response, we measured Nrf2 and Nqo1 transcript lev-
els following lithium treatment. Under conditions of stress, Nrf2 activates a program of genes
meant to counteract stressful conditions and protect the cell. As the stress stimulus subsides,
we would expect the helpful Nrf2 response to subside as well. We previously found that Nrf2
and Nqo1 are elevated in R236H/+ mice [26] and that a further increase in Nrf2 is helpful and
leads to a decrease in GFAP in R236H/+ mice [27]. We also found that the Nrf2 activation was
diminished in the context of protective over-expression of αB-crystallin [45]. For the current
study, we used Nrf2 and Nqo1 as indicators of the antioxidant stress response and found that
after lithium treatment, the stress response had decreased. This data also suggests that the help-
ful effects of lithium are not mediated through Nrf2 pathways since lithium did not increase
Nrf2 and Nqo1 transcripts.
Ultimately the levels of GFAP in brain reflect a balance between synthesis and degradation.
The half-life of GFAP in vivo has only been studied twice, once using a radioactive tracer (and
reporting a half-life of ~9 weeks in mouse spinal cord) [46] and once using stable isotopic label-
ing for a more global measure of turnover (and reporting a half-life of 28 days in mouse brain)
[47]. Whether these kinetics are applicable when some of the GFAP is mutated and present in
protein aggregates is the subject of active investigation. Nevertheless, we found no evident
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difference in the degree of GFAP suppression when we doubled the treatment duration from 4
to 8 weeks, suggesting either that lithium had reached its maximal effect with these doses or
that adaptation to the lithium takes place.
Variability between brain regions
We found noticeable differences in the degree of GFAP suppression by lithium as a function of
anatomic region. In mouse, rat, and human, baseline levels of GFAP vary considerably across
regions [48, 49], which could be attributed to differences in astrocyte density and/or heteroge-
neity among distinct astrocyte populations. In addition, it is possible that non-uniformity of
lithium distribution within the CNS following peripheral administration could contribute to
variability in response [50], although in our hands the GFAP response was greater in corpus
callosum than hippocampus (the opposite direction of the differences in drug concentration
found by Thellier [50]).
Toxicity of lithium treatment
Lithium is known to have a narrow therapeutic range, with plasma concentrations of 0.5–1.2
meq/L considered a safe therapeutic range in human patients [51]. Toxic effects usually occur
at 1.5 meq/L and dangerous life-threatening side effects can occur at concentrations above 2.0
meq/L [51]. In our studies we focused on doses ranging from 0.3% to 0.7% in the diet, yet even
with 0.5% LiCl for 4 wks, serum concentrations were at or above 1.5 meq/L (1.5 mM Li). Lith-
ium kinetics differ between humans and mice [52], which complicates the linkages between
dosing and blood levels. Nevertheless, the already broad spectrum of lithium targets appears to
widen at higher concentrations [53]. It is possible cell death could account for changes in
GFAP expression and this is a limitation of the present study. However, examination of limited
tissues did not reveal any necrotic tissue or pyknotic nuclei in lithium-treated brains, and pre-
vious studies in rats also did not find any morphological changes or cell death following toxic
levels of lithium [54, 55].
In conclusion, we show that lithium decreases GFAP in a mouse model of Alexander disease,
possibly through transcriptional mechanisms involving STAT3. However, its narrow therapeutic
range complicates the use of lithium for therapeutic purposes. In addition, there is little experi-
ence in using lithium in young pediatric patients (who constitute a significant portion of the
Alexander disease population), although recently lithium was reported to be well tolerated in a
small trial conducted for Canavan disease on 6 patients with an average age of 9.5 months [56].
Supporting Information
S1 Fig. LiCl administered daily via i.p. injection for 30 days does not have significant effects
on GFAP-R236H/+ mice. (A) All mice survived the LiCl i.p. treatment. (B-C) R236H/+ mice
have lower body weights compared with +/+ littermates and LiCl treatment does not change
this in male (B) or female mice (C) (N = 7–10 mice per female group and 4–10 mice per male
group). (D-E) LiCl i.p. treatment decreased GFAP in parietal cortex (including underlying
white matter) of female R236H/+ mice (D, N = 5–6 mice per group) and in cerebellum of
R236H/+ male mice (E, N = 4–5 mice per group) but did not affect GFAP levels in other brain
regions. Error bars are SD. P< 0.0001, P< 0.001, P< 0.01, P< 0.05.  is versus
+/+ control in B and C.
(EPS)
S2 Fig. LiCl administered via 0.3% LiCl food pellets for 30 days does not have significant
effects on female GFAP-R236H/+ mice. (A) All mice survived the 0.3% LiCl food treatment.
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(B) R236H/+ mice have lower body weights compared with +/+ littermates and LiCl treatment
does not change this (N = 5–9 mice per group). (C) 0.3% LiCl food treatment did not affect
GFAP levels in any brain regions (N = 6–9 mice per group). Error bars are SD. P< 0.001.
(EPS)
S3 Fig. 0.5% LiCl in food for 4 wks decreases GFAP in female GFAP-R236H/+ mice. (A)
+/+ LiCl and R236H/+ LiCl mice have lower body weights than control mice (N = 4–6 cages,
5–11 mice per group). (B) LiCl decreases GFAP in all regions of R236H/+ mice, except olfac-
tory bulb (N = 4–6 cages, 5–10 mice per group). Error bars are SEM. P< 0.0001,
P< 0.001, P< 0.05.  is versus +/+ control in A.
(EPS)
S4 Fig. LiCl administered via 0.7% LiCl food pellets for 4 wks decreases GFAP in only a few
brain regions. (A) 93.7% (15/16) of R236H/+ mice survived 4 wks of LiCl treatment, while all
+/+ mice survived LiCl treatment and all mice survived control treatment. (B-C) 0.7% LiCl
treatment decreased body weights in +/+ and R236H/+ male (B) and female (C) mice (N = 4–5
cages, 5–8 mice per male group and 4–6 cages, 5–12 mice per female group). (D) 0.7% LiCl
food treatment decreased GFAP in cerebellum and cervical spinal cord of male R236H/+ mice
(N = 4–5 cages, 5–8 mice per group). (E) 0.7% LiCl treatment decreased GFAP in olfactory
bulb and cerebellum of female R236H/+ mice (N = 4–5 cages, 6–11 mice per group). Error bars
are SEM. P< 0.0001, P< 0.001, P< 0.01, P< 0.05.  is versus +/+ control and ‡ is
R236H/+ control versus R236H/+ LiCl in B and D.
(EPS)
S5 Fig. 0.5% LiCl in food for 4 wks caused variable effects on p70S6K and GSK3β. (A-B)
Immunoblots of male cortex showed substantial variability in the autophagy protein p70S6K
and phospho-p70S6K with LiCl treatment. All p70S6K samples were run together on the same
gel and all p-p70S6K samples were run together on a second gel. Separation of the lanes by the
black boxes was done to align the p70S6K samples with their corresponding p-p70S6K sample
from the same mouse. (C-D) LiCl treatment did not consistently increase phosphorylation of
GSK3β in GFAP+/+ and R236H/+ hippocampus. (E-F) LiCl treatment did not change P62 lev-
els in male cortex (N = 3–5 mice from 3–5 cages per group). Error bars are SEM. P< 0.05.
(EPS)
S6 Fig. Uncropped blots.Whole uncropped blots for STAT3 and p70S6K.
(EPS)
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